While some of the survival pathways activated by CXCL12 in CLL are known, including Akt and ERK1/2, this approach enabled the identification of additional signaling targets and novel phosphoproteins that could have implications in CLL disease and therapy. The gene discussed is CXCL12; the disease is B-cell chronic lymphocytic leukemia.